Request for Proposal
Transforming the Future of Tobacco Cessation & Reduction
Status: RFP is Closed
Request for Proposal
RFP Title
NineSigma, representing GSK Consumer Healthcare, invites proposals for new technologies to ENHANCE or REIMAGINE current approaches to tobacco cessation and reduction.
GSK Consumer Healthcare currently is the largest global marketer of nicotine replacement therapies (NRT) for smoking cessation. We serve patients in over 20 countries, including the US, Canada, across Europe, and Australia.
GSK Consumer Healthcare strives to transform the future of self-care. We hope to leverage the wisdom of experts within the fields of nicotine and tobacco research to identify areas of critical and emerging unmet needs within the tobacco cessation and reduction space and collaborate with key scientific partners to help deliver upon them.
The challenge focuses around the following areas of interest for GSK. Those with technologies that can fit or be adapted to any of these areas are asked to submit a brief proposal through the NineSights web portal (details below).
Differentiated Nicotine Replacement Therapy
GSK seeks differentiated oral and transdermal dosage forms for our NRT products as part of our Smokers’ Health franchise. Innovation may deliver superior efficacy or enhanced user experience.
Additionally, we are always seeking to improve how patients utilize our products by innovating in areas such as (but not limited to):
Digital Health & Behavioral Support Platforms
Behavioral support is shown to improve a smoker’s chances of quitting. GSK is interested in connected devices and technology platforms which help consumers quit or reduce smoking as well as manage their respiratory health. Areas of interest broadly include (but are not limited to):
Open Ended
If you could collaborate with GSK to improve any aspect of the lives of those struggling with a nicotine addiction, what would that be and how can GSK help?
GSK notes that possible approaches might include, but are not limited to:
Approaches that provide alternatives to smoking but do not promote a nicotine-free lifestyle are not of interest to GSK.
Your response should address the following: